Kornimate/medical-research-clean huggingface dataset:
a multicenter study of intensive concomitant chemoradiotherapy with filgrastim (gcsf) for patients with locoregionally advanced head and neck cancer

Conditions: Head and Neck

Summary: the goal of the study is to test a particular combination of drugs and determine their ability to completely eliminate head and neck cancer.


Eligibility criteria:
eligibility criteria: 1. patients with stage iv carcinoma of the nasal or oral cavity, nasopharynx pharynx, larynx, paranasal sinuses, cervical esophagus, or hypopharynx are eligible. patients with stage iii carcinoma of the nasopharynx, base of tongue and hypopharynx are also eligible. therapy is given with curative intent. prior to entry in the study the resectability and standard treatment options for each patient will be determined during a joint evaluation by a team composed of an attending surgeon, a radiation oncologist and a medical oncologist. in addition the timing and feasibility of surgery will be determined in each patient prior to initiation of therapy. the unequivocal demonstration of distant metastasis confers in eligibility. 2. measurable disease is not required, but all disease will be carefully evaluated. 3. patients must have a histologically or cytologically confirmed diagnosis of squamous cell carcinoma or lymphoepithelioma. 4. patients must have not received prior chemotherapy or radiotherapy. 5. patients must have performance status of \>60% 6. patients must have a wbc count of \>3.5, an anc count \>1500 and a platlet count of \>100,000. 7. the serum creatinine must be equal to or less than 1.5 m/dlor the calculated creatinine clearance must exceed 50cc/min. 8. patient must be free of significant infection or other severe complicating medical illness. 9. pregnancy will constitute an absolute contraindication to entrance on this protocol. females of child-bearing age should be using adequate contraception.

Keywords: cancer advanced oral cavity larynx
glycemic control of carvedilol versus metoprolol in patients with type ii diabetes mellitus and hypertension

Conditions: Hypertension

Summary: to evaluate the effects of two different antihypertensive medications in the drug class of beta-blockers on control of glucose in type ii diabetic patients with high blood pressure.


Eligibility criteria:
inclusion criteria: * patients at screening must be insulin producing type ii diabetics (c peptide positive). * must have a history of mild to moderate hypertension (140-179 systolic; 90-1-9 diastolic). * must be on stable regimen of ace (angiotensin converting enzyme) / arb (angiotensin receptor blocker) treatment alone or in combination with other treatments. * patient''s laboratory result for hba1c must be 6.5 - 8.5 (drug treated) or 6.5 - 7.5 (diet alone). * must be on a stable antidiabetic regimen (drug treated or diet alone). exclusion criteria: * patients using beta-blocker therapy.

Keywords: type 2 diabetes hypertension beta-blockers
study to assess platelet dysfunction with verify now assay

Conditions: Platelet Aggregation Defects

Summary: the purpose of this study is to conduct a verify now assay to detect platelet aggregation defects in patients with myelodysplastic syndrome(mds), immune thrombocytopenia purpura (itp) and myeloproliferative disorders (mpd).

verify now is a rapid, simple, point-of service assay to measure platelet aggregation. the verify now assay is designed to assess platelet function based on the ability of activated platelets to bind fibrinogen. it is hoped that this study will detect the subtle platelet functional abnormalities in patients with hematological disorders.

Eligibility criteria:
inclusion criteria - patients with common blood disorders such as immune thrombocytopenia purpura(itp) myelodysplastic syndrome mds)and myeloproliferative disorders (mpv) exclusion criteria - patients with normal platelet counts

Keywords: verify now assay for hematological disorders
emotional regulation in people with co-occurring posttraumatic stress disorder and substance use disorder

Conditions: Posttraumatic Stress Disorder; Substance Use Disorders; Emotional Regulation

Summary: the aim of this project is to look at emotional regulation in people with posttraumatic stress disorder (ptsd) and substance use disorder (sud). this study will explore how people with ptsd-sud regulate their emotions and how this might explain the relationship between these two disorders. in turn, this may inform effective treatment strategies for people with comorbid ptsd-sud. emotional regulation refers to the way in which people process and respond to their emotions. ptsd and sud commonly cooccur and this is associated with adverse outcomes including high rates of relapse, overdose, and suicide. we therefore need effective treatments to address this clinical concern. evidence suggests emotional regulation might be important in the development and maintenance of ptsd and sud and therefore it might be a useful target for treatment. however, most research in this area has been quantitative and has not considered how gender, social circumstances and trauma or substance type might affect the way people regulate their emotions. this study will recruit 40 adults with trauma histories and ptsd who are currently receiving treatment in a community drug and alcohol service for their substance use. participants will be interviewed to explore how they regulate their emotions and how this relates to their social circumstances. this study will also explore whether gender, substance or trauma type affect the way people regulate their emotions. we hope this will help to improve treatment for people with ptsd and sud.


Eligibility criteria:
inclusion criteria: * • adults aged 18+ * receiving treatment from a community substance use service at the time of the study. * experienced, witnessed or been confronted with at least one traumatic event (according to ptsd diagnostic scale for dsm-5) (pds-5) (foa, 2016). * participant endorses at least 3 ptsd symptoms from criterion b-e, measured using the pds-5. * able to communicate and understand english sufficiently to engage in a qualitative interview. exclusion criteria: * • staff recommend the individual should not take part in the study * the individual is unable to provide informed consent

Keywords: ptsd posttraumatic stress disorder substance use disorders trauma emotional regulation
an extension study to evaluate the long-term safety and durability of effect of lum001 in the treatment of cholestatic liver disease in subjects with alagille syndrome (algs)

Conditions: Alagille Syndrome

Summary: the purpose of this extension study is to determine the long-term safety and tolerability of an investigational treatment (lum001 also known as maralixibat) in children with algs who have completed participation in a core lum001 treatment protocol. efficacy will be assessed by evaluating the effect of lum001 on pruritus, biochemical markers of pruritus, as well as biochemical markers of cholestasis and liver disease.


Eligibility criteria:
participation for an individual patient is expected to be approximately 72 weeks. patients who complete 72 weeks of treatment may be eligible to receive treatment for up to 52 weeks during the follow-up treatment period and patients who completed the 124 weeks of treatment may be eligible to enter the additional long-term follow-up period.
impact of treatment induced premature menopause on quality of life

Conditions: Menopause, Premature

Summary: to understand the impact of treatment induced menopause on quality of life and sexuality following blood and marrow transplantation.


Eligibility criteria:
inclusion criteria: * premenopausal * sexually active women * able to read and write english exclusion criteria: - postmenopausal females
evaluation the neurocognitive functions among children with enlargement adenoid and tonsils, before and after tonsillectomy or adenotonsillectomy

Conditions: Child Neurocognitive Function

Summary: evaluation the neurocognitive functions among children with enlargement adenoid and tonsils, before and after tonsillectomy or adenotonsillectomy


Eligibility criteria:
inclusion criteria: * children between 6-18 years old. * children with enlarged tonsils or adenoids. * a sleep lab test before the procedure. exclusion criteria: * children under 6 years old and above 18 years old. * patience that treated in adhd / addor with other neurocognitive disorder.
topiramate and cerebrovascular response in migraineurs

Conditions: Migraine Disorders

Summary: the purpose of this study is to evaluate the effect of topiramate on cerebrovascular reactivity and mean flow velocity to photic stimulation in migraineurs.


Eligibility criteria:
inclusion criteria: * aged 18 to 65 years * newly-diagnosed patients with migraine without aura (international headache society classification) * symptom frequency (at least 2 episodes of migraine attack/month) exclusion criteria: * prior use of preventive medication * patients with cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking) * patients who take antihypertensive agent or antidepressant * patients who were pregnant, breast-feeding or actively smoking * patients with neurological or cerebrovascular diseases
serum clozapine and cognition

Conditions: Schizophrenia

Summary: this study aim to investigate the relationship between serum levels of clozapine and cognitive performance in patients with icd-10 schizophrenia and treated with clozapine monotherapy. the hypothesis is that higher serum levels of clozapine are associated with cognitive dysfunctions. furthermore, ecg changes and the relation to serum level of clozapine are studied. the design is cross-sectional.


Eligibility criteria:
inclusion criteria: * treated with clozapine for minimum 6 months. * fixed dosage of clozapine last month before inclusion. exclusion criteria: * substance misuse. * depression (calgary depression score ≥7). * somatic disease that interfere with cognitive performance. * treatment with benzodiazepines (half-lives \>15 hours not allowed up 14 days prior inclusion and during study. half-lives \< 15 hours not allowed 3 days prior cognitive testing). * electroconvulsive therapy. * treatment with other antipsychotics. * withdrawal of informed consent. * compulsory measures. * treatment with anticholinergics except for atropine drops administered sublingually. * changes in use of tobacco last month before inclusion.

Keywords: clozapine schizophrenia cognition t-wave morphology
fci in post-operative low grade gliomas

Conditions: Glioma

Summary: the aim of this pilot study is to explore the utility of a new imaging technique, called field cycling imaging (fci), in postoperative low grade gliomas. the main question it aims to answer is if fci can differentiate subtypes of low grade gliomas. participants will have one fci scan.

standard clinical magnetic resonance imaging (mri) is the mainstay of diagnosis in brain lesions. it is a powerful imaging technique for the non-invasive investigation of the brain and has been an incredibly successful technology since its commercialisation in the 1980s largely due to its excellent spatial resolution and ability to distinguish multiple tissues in multiple planes. when exogenous contrast agents are used, mri can demonstrate the breakdown of the blood-brain barrier and provide additional physiological information. however, standard mri has limitations in determining the subtypes of tumours, which originate from different cells and therefore contain differing types of proteins. the aim of this project is to establish if there is a difference in the relaxometry (i.e., loss of mri signal over time) characteristics of different brain lesions using field cycling imaging (fci), which is a new technology being developed at the university of aberdeen. fci combines the use of a moderately high magnetic field with the ability to probe low magnetic fields so that one can preserve image resolution while also exploiting the high contrast present at low magnetic fields. this provides quantitative data on the molecular dynamics in the tissues, completely non-invasively. for this study, the research team will use fci to try to establish if there is a difference in the relaxometry characteristics of different low-grade gliomas. ten patients with postoperative low grade glioma will be included. each participant will be asked to undergo one fci scan only. fci images will be acquired on dedicated equipment, specifically built for the purpose of imaging human volunteers and patients. participants will carry on receiving their routine clinical care before and after their scan.

Eligibility criteria:
inclusion criteria: * patients with post operative low-grade glioma. * capacity to give informed consent. * capacity to co-operate with the scanning procedures and duration. * age 16 and above. * participants who can pass through a 50 cm-diameter circular hoop to ensure they will be able to fit inside the scanner. * participants who meet the safety criteria for undergoing an mri scan. * participants must be mobile enough to be positioned onto the fci scanner couch. exclusion criteria: * mri-incompatible conditions, as detected in the mri safety screening form. * restrictions to mobility that would prevent the correct positioning in the scanner by trained research radiographer (e.g., severe kyphosis). * participants who are unable to give fully informed consent. * women who are pregnant. * participants who are unable to understand or communicate in english. * patients who suffer from claustrophobia.
treatment of coronary in-stent restenosis by a sirolimus (rapamycin) coated balloon or a paclitaxel coated balloon

Conditions: DES In-stent Stenosis

Summary: the aim of the study is to investigate the non-inferiority of the new sirolimus-coated balloon catheters in comparison to the paclitaxel-coated sqp with regard to acute tolerance, safety and efficacy in coronary des in-stent restenosis.

the aim of the study is to investigate the non-inferiority of the new sirolimus-coated balloon catheters in comparison to the paclitaxel-coated sqp with regard to acute tolerance, safety and efficacy in coronary des in-stent restenosis. patient population will consist of male and female adults suffering from coronary drug-eluting stent (des) restenosis, which is to be treated by a study balloon according to the inclusion and exclusion criteria as defined below. in late lumen loss lesion (difference between the angiographic in-lesion mld post procedural and at 6 months follow-up) will be evaluated by quantitative coronary angiography (qca). the study will be performed as a single-blind, sqp controlled study in 4 - 6 study centers in 50 patients.

Eligibility criteria:
inclusion criteria: * 18 years of age * clinical evidence of stable or unstable angina (acute coronary syndrome) or a positive functional study * patients with ≤ 2 primary drug-eluting stent in-stent restenosis (des-isr) lesions (≥ 70% diameter stenosis by visual estimation or ≥ 50% and positive functional study) including margin stenosis with max 5mm distance to the stent. exclusion criteria: * chronic renal insufficiency with serum creatinine levels \> 2.0 mg per deciliter * known hypersensitivity or contraindications to aspirin, heparin, clopidogrel, ticlopidine or sirolimus, and sensitivity to contrast media not amenable to premedication * concomitant medical illness associated with a life-expectancy of less than two year * lesion length (isr) \> 35 mm, vessel diameter \< 2.5 mm
clinical trial : complications of in the bag iol versus optic capture of iol in pediatric cataract surgery

Conditions: Posterior Capsule Opacification; Postoperative Complications

Summary: this prospective, randomized, clinical trial looks to compare children undergoing congenital cataract surgery with intraocular lens (iol) implantation in terms of visual axis obscuration as well as postoperative complications such as glaucoma, inflammation and iol centration when iol fixation is performed using two different techniques : 1) conventional in the bag iol implantation with anterior vitrectomy, and, 2) posterior optic capture of the iol through the posterior capsulorhexis without any vitrectomy. 61 eyes of 61 children randomized to receiving iol implantation using one of the two techniques will be followed up until 12 months postoperatively.

this prospective, randomized, controlled, clinical trial compares visual axis obscuration as well as intra and postoperative complications in children undergoing cataract surgery with iol implantation using one of two techniques : 1. in the bag iol with limbal anterior vitrectomy 2. posterior optic capture of iol optic through the posterior capsulorhexis without any vitrectomy. the aim is to evaluate whether avoiding anterior vitrectomy is a feasible option, particularly younger children, where anterior vitrectomy has become an integral part of the routine surgical strategy. all children will be evaluated at 1 month, 3 months, 6 months and 12 months postoperatively.

Eligibility criteria:
inclusion criteria: * uncomplicated cataract, * unilateral or bilateral cataract, * corneal diameter \>9.0mmhg exclusion criteria: * pre-existing glaucoma, * uveitis, * ocular comorbidity, * microphthalmos, * microcornea, * parents not consenting to participate in study, * traumatic cataract
s1 plus anlotinib in treating patients with refractory or relapsed small-cell lung cancer

Conditions: Small Cell Lung Cancer Recurrent

Summary: the purpose of this study is to assess the efficacy and safety of s1 combination with anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at least one standard chemotherapy.

although sclc is very responsive to initial treatment, most patients relapse with relatively resistant disease.these patients have a median survival of only 4 to 5 months when treated with further systemic therapy. improvements in therapy for relapsed sclc are much needed.the purpose of this study is to assess the efficacy and safety of s1 combination with anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at least one standard chemotherapy.

Eligibility criteria:
inclusion criteria: * histological or cytologically confirmed small cell lung cancer; * systemic chemotherapy that has previously received at least one or more lines regimen, followed by disease progression or recurrence; * age 18-75 years,ecog ps:0-2,life expectancy of more than 3 months * participants had at least one measurable target lesion by recist1.1 * the main organ function meets the following criteria:absolute value of neutrophils ≥ 1.5 × 109 / l, platelets ≥80 × 109 / l, hemoglobin ≥ 80 g / l;total bilirubin ≤ 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal value (if liver metastasis, ≤ upper limit of normal value 5 times), serum creatinine ≤ 1.5 times the upper limit of normal; * patients should participate in the study voluntarily and sign informed consent exclusion criteria: * patients who have been used anti-angiogenesis inhibitors,such as (such as sunitinib,bevacizumab,endostar et al. * subjects with symptomatic brain metastases; * patients whose primary lesion with active bleeding within 4 months * hypertension, which is uncontrolled by the drug, is defined as: systolic blood pressure ≥ 160 mmhg, or diastolic blood pressure ≥ 100 mmhg * patients with active or unable to control serious infections * patients who are pregnant or breastfeeding.
effectiveness of a wheelchair skills training program for power mobility users: a randomized controlled trial

Conditions: Movement Disorders

Summary: this is a 3-year multi-centre, single-blinded, randomized controlled trial (rct) to test the hypothesis that wheelchair skills training (using a systematic training program called the wheelchair skills training program) improves wheelchair skills and safety of 144 powered wheelchair users. a second objective is to assess the effects of age, sex, training centre, and participant experience on outcomes, assessing the retention of benefits and assessing the impact of training on other important outcomes.


Eligibility criteria:
inclusion criteria: * new or experienced powered wheelchair users * use or are expected to use powered wheelchairs for at least 4 hrs/week * have access to a powered wheelchair with a suitable range of controller settings (i.e. able to climb a 5cm level change) for testing and training * equal or greater than 18 years of age * able to follow directions in either french or english (whichever is in use at the participating site) * have the potential to operate their powered wheelchairs independently * have room for improvement (in the opinion of the potential participant's clinician) * requires no more than minimal assistance for communication and auditory comprehension (in the opinion of the potential participant's clinician) * able to follow 2-step commands * demonstrate the ability to attend training sessions during the intake session * competent to provide their own informed consent * able to be comfortably seated in the powered wheelchairs that will be used for the study (if not their own). exclusion criteria: * use or are expected to use a scooter * have a rapidly progressive disorder (e.g. amyotrophic lateral sclerosis or terminal cancer) * have significant visual impairments (legally blind) * have unstable medical conditions (e.g. angina, seizures) * have emotional problems (e.g. severe anxiety, depression) that might make participation unsafe or unpleasant

Keywords: rehabilitation wheelchairs safety disability evaluation motor skills
effect of intravitreal bevacizumab on focal edema with hard exudates secondary to diabetic retinopathy

Conditions: Diabetes Complications

Summary: purpose: to evaluate the efficacy of intravitreal bevacizumab (ivb) on focal edema with hard exudates secondary to diabetic retinopathy. design: prospective interventional case series. participants: ten eyes of 10 consecutive patients showing focal edema with hard exudates secondary to diabetic retinopathy which are not eligible for focal laser photocoagulation due to central location (\< 500 µm from fovea).


Eligibility criteria:
inclusion criteria: 1. patients of either gender aged \> 18 years 2. patients with type 2 diabetes 3. central macular thickness \> 300 µm on oct 4. eyes not eligible for focal laser photocoagulation due to the central location of hard exudates (\< 500 µm) 5. an area of retinal thickening less than 2 disc areas in diameter 6. 67% or more of leakage associated with microaneurysms exclusion criteria: 1. eyes with history of laser photocoagulation or pharmacological intervention for dme on study eye 2. eyes with any pharmacologic intervention on fellow eye within 6 months 3. history of ocular diseases other than diabetic retinopathy 4. surgical history other than cataract extraction with intraocular lens implantation 5. panretinal photocoagulation within 3 months of enrollment 6. media opacity 7. any thromboembolic event within 6 months, or evidence of active cardiac ischemia on electrocardiogram (ecg) at time of screening.

Keywords: clinically significant macular edema diabetic macular edema focal edema focal laser photocoagulation hard exudates intravitreal bevacizumab